The US Food & Drug Administration’s approval of Florida’s plan to import drugs from Canada is clearly an important milestone in the decades-long debate over how to address international pricing disparities for prescription drugs.
The news was also appropriately recognized as not an immediate and significant change in the US market, particularly since – as FDA stressed in making the 5 January announcement – there are still many hurdles for Florida and its contractor to clear before actual shipments of Canadian drugs can begin